Compare Corsair Gaming Inc (CRSR) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corsair Gaming Inc vs Novartis AG — how do they compare? Corsair Gaming Inc trades at $13.63 (market cap $1.42B), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 189.1× Corsair Gaming Inc's market cap, and Novartis AG pays a 3.31% dividend while Corsair Gaming Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Corsair Gaming Inc for 25 Days and Novartis AG for 82 Days on average.
| CRSR | NVS | |
|---|---|---|
Market Cap | $1.42B | $268.57B |
Volume | 1,160,938 | 1,532,573 |
Sector | Technology | Health |
52-Week High | $14.35 | $168.62 |
52-Week Low | $4.58 | $121.80 |
Typical Hold Time | 25 Days | 82 Days |
Enterprise Value | $1.41B | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Corsair Gaming (CRSR) trades at $13.09, down 3.68% today but showing strong earnings momentum with three consecutive quarterly beats. The stock maintains a bullish technical signal with current price near pivot point support at $13. Recent Q2 2026 results exceeded expectations with EPS of $0.23 versus $0.07 estimate, driving positive sentiment from institutional investors including Canada Pension Plan's new position. The company continues product innovation with VOXARA microphone launch and strategic acquisitions like Trak Racer assets.
While valuation appears elevated with P/E of 42.23, improving profitability trends and raised 2026 guidance support upside potential. Key risks include competitive gaming peripherals market and inconsistent cash flow generation. Analyst consensus shows mixed sentiment with 36% buy ratings but average price target of $12.40 suggests limited near-term upside from current levels.
NVS trades at $143.11, down 0.12% on the day, with a bearish technical signal and mixed earnings history including a recent Q1 2026 miss. The company maintains strong profitability with a 22.5% net income margin and 30.55% ROE, while recent news highlights a major $7.8B licensing deal with China's Abogen and ongoing investor scrutiny following clinical trial setbacks.
The outlook is cautious; analyst consensus is a Hold with a $146 price target, but risks include pipeline disappointments and M&A execution. Upside hinges on successful drug launches and deal integration, while downside stems from competitive pressures and regulatory challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Corsair Gaming Inc
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment
Read more on CRSR →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
